Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation

Abraham S. Kanate(HonorHealth), Mehdi Hamadani(Medical College of Wisconsin), Aaron Cumpston(West Virginia University Hospitals), Laura C. Michaelis(Medical College of Wisconsin), Parameswaran Hari(Medical College of Wisconsin), Anita D’Souza, Jennifer Boyd(Medical College of Wisconsin), Wael Saber(Medical College of Wisconsin), Timothy S. Fenske(Medical College of Wisconsin), Ehab Atallah(Medical College of Wisconsin), William R. Drobyski(Medical College of Wisconsin), Karen-Sue Carlson(Medical College of Wisconsin), J. Douglas Rizzo, Michael Craig(Edith Cowan University), Marcelo C. Pasquini(Cleveland Clinic), Mary M. Horowitz(Medical College of Wisconsin), Pamela Bunner(West Virginia University), Guru Subramanian Guru Murthy(Medical College of Wisconsin), Alexis Visotcky(Medical College of Wisconsin), Kwang Woo Ahn(Medical College of Wisconsin)
Transplantation and Cellular Therapy
April 12, 2017
10.1016/j.bbmt.2017.04.009
Cited by 11

Related Papers

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Solid Cancers after Bone Marrow Transplantation
|New England Journal of Medicine|1997|968